ResMed Files Patent Infringement Action against Fisher & Paykel
ResMed files new infringement action against Fisher & Paykel’s Simplus, Eson and Eson 2 masks in the International Trade Commission to stop their importation to and sale in the United States
ResMed also files new district court action seeking monetary damages for and injunction against sales of F&P’s Simplus, Eson and Eson 2 masks
September 03, 2018 11:40 KST
SAN DIEGO--(Business Wire / Korea Newswire) September 03, 2018 -- ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical device company and innovator in sleep apnea and respiratory care, today filed a petition with the United States International Trade Commission to stop the infringement of its patented technology by New Zealand-based medical device manufacturer Fisher & Paykel Healthcare.
In the International Trade Commission, ResMed seeks an order banning the importation and sale in the United States of Fisher & Paykel’s Simplus full face mask, Eson nasal mask and Eson 2 nasal mask, for infringing five ResMed patents relating to mask system and cushion design. ResMed’s new case asserts that:
· F&P’s Simplus infringes each of the five asserted ResMed patents.
· F&P’s Eson and Eson 2 infringe three of the five patents, which relate to modular mask systems.
Also today, ResMed filed a new lawsuit in the United States District Court for the Southern District of California, seeking monetary damages based on Fisher & Paykel’s patent infringement, plus an injunction against future sales of infringing masks in the United States.
“ResMed provides millions of consumers with high-quality products, which are the direct result of substantial and sustained investments in research and development, as well as a focus on each consumer’s therapy needs,” said ResMed global general counsel and chief administrative officer David Pendarvis. “We will defend our intellectual property wherever necessary to ensure that patients worldwide continue to receive the high-quality care they deserve, and are confident that when the ITC and the District Court hear all the evidence, ResMed will prevail in these cases.”
ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 5 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world’s best tech-driven medical device company - improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries. ResMed.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180831005473/en/
- ResMed Inc. Completes $500M Private Placement Debt Offering
- The Lancet Publishes: More Than 936 Million Have Obstructive Sleep Apnea Worldwide
- New Analysis Shows Sleep Apnea More Common in Americas than Previously Thought
- ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries
- Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought